Johnson & Johnson vs Eli Lilly and Company
A head-to-head of Johnson & Johnson (JNJ) and Eli Lilly and Company (LLY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | JNJ | LLY |
|---|---|---|
| Market Cap | $555.94B | $823.33B |
| P/E (TTM) | 25.81 | 38.32 |
| Forward P/E | 17.72 | 24.85 |
| P/S | 5.77 | 11.40 |
| P/B | 8.58 | 32.62 |
| EV/EBITDA | 17.48 | 22.78 |
| Dividend Yield | 1.80% | 0.55% |
| Profit Margin | 21.83% | 34.99% |
| Gross Margin | 67.88% | 83.04% |
| Operating Margin | 27.17% | 45.56% |
| Revenue Growth (YoY) | +9.91% | +55.54% |
| FCF Yield | 3.13% | 1.26% |
| Debt / Equity | 67.73 | 139.02 |
| Current Ratio | 1.03 | 1.50 |
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.